Skip to main content
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 1998 Dec 7;12(1):60–64. doi: 10.1002/(SICI)1098-2825(1998)12:1<60::AID-JCLA10>3.0.CO;2-M

Assays of antibodies to a C‐terminal peptide or the entire β‐subunit of human chorionic gonadotropin

Sten Z Cekan 1,, Ana‐Rosa Aedo 1
PMCID: PMC6808127  PMID: 9484671

Abstract

Antibodies were assayed in serum samples obtained from rabbits or women immunized with a vaccine based on a C‐terminal peptide (109–145; CTP) of the β‐subunit of human chorionic gonadotrophin (hCG) with use of a ligand‐binding assay. In rabbit samples, two types of assay were used. The first “homologous” type was based on CTP as tracer and standard. In the second “heterologous” type, directly reflecting the hCG‐neutralizing potency, hCG was used as tracer and standard. The equilibrium constants of antibodies were substantially higher in the homologous than in the heterologous assay, indicating that the fit of hCG to the antibodies was worse than that of CTP. This was further confirmed by very low cross‐reaction values of hCG. In addition, hooks occurred in Scatchard plots when the heterologous assay type was used, both with rabbit and human samples. However, a high correlation between the results of the homologous and heterologous assay was observed (r = 0.97; P <0.05). Therefore, it is envisaged that the possibility of using the homologous, analytically less complex assay will be further investigated in future clinical studies. Antibodies raised in women to the β‐subunit of hCG had equilibrium constants higher by one to two orders of magnitude than those of the anti‐CTP antibodies. The present definition of a threshold pregnancy‐preventing level of antibodies disregards their avidity. It is suggested that in future studies, the problem of varying avidity could be solved by individually adjusting the threshold levels with respect to antibody avidity. J. Clin. Lab. Anal. 12:60–64, 1998. © 1998 Wiley‐Liss, Inc.

Keywords: pregnancy, immunization, quantitation, threshold, contraception

References

  • 1. Hearn JP, Webley GE, Gidley‐Baird AA: Chorionic gonadotrophin and embryo‐maternal recognition during the peri‐implantation period in primates. J Reprod Fert 92: 497–509, 1991. [DOI] [PubMed] [Google Scholar]
  • 2. Talwar GP, Singh O, Pal R, Chatterjee N, Sahai P, Dhall K, Kaur J, Das SK, Suri S, Buckshee K, Saraya L, Saxena BN: A vaccine that prevents pregnancy in women. Proc Natl Acad Sci 91: 8532–8536, 1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Stevens VC, Powell JE, Lee AC, Griffin D: Antifertility effects of immunization of female baboons with C‐terminal peptides of the β‐subunit of human chorionic gonadotropin, Fertility Sterility 36: 98–105, 1981. [DOI] [PubMed] [Google Scholar]
  • 4. Jones WR, Judd SJ, Ing RMY, et al.: Phase I clinical trial of a World Health Organization birth control vaccine. Lancet 1295–1298, 1988. [DOI] [PubMed]
  • 5. Powell JE, Lee AC, Tregear GW, Niall HD, Stevens VC: Characteristics of antibodies raised to carboxy‐terminal peptides of hCG β‐subunit. J Reprod Immunol 2: 1–13, 1980. [Google Scholar]
  • 6. Scatchard G: The attractions of proteins for small molecules and ions. Ann NY Acad Sci 51: 660–672, 1948. [Google Scholar]
  • 7. Munson PJ: User's Guide to LIGAND: Data analysis and curve‐fitting for ligand binding experiments. Laboratory of Theoretical and Physical Biology, NIHHD, Bethesda, MD, 1987. [Google Scholar]
  • 8. Dirnhofer S, Klieber R, De Leeuw R, et al.: Functional and immunological relevance of the COOH‐terminal extension of human chorionic gonadotropin: Implications for the WHO birth control vaccine. FASEB 7: 1381–1385, 1993. [DOI] [PubMed] [Google Scholar]
  • 9. Dirnhofer S, Wick G, Berger P: The suitability of human chorionic gonadotropin (hCG)‐based birth‐control vaccines. Immunology Today 15: 469–474, 1994. [DOI] [PubMed] [Google Scholar]
  • 10. Benagiano G: The WHO birth control vaccine. FASEB 8: 784–786, 1994. [DOI] [PubMed] [Google Scholar]
  • 11. Griffin PD: Birth‐control vaccines. Immunology Today 16: 502, 1995. [DOI] [PubMed] [Google Scholar]
  • 12. Moyle WR, Lin C, Corson RL: Quantitative explanation for increased affinity shown by mixtures of monoclonal antibodies: Importance of a circular complex. Mol Immunol 30: 439–452, 1983. [DOI] [PubMed] [Google Scholar]
  • 13. Talwar GP: Immuno‐contraception. Current Opin Immunol 6: 698–704, 1994. [DOI] [PubMed] [Google Scholar]
  • 14. Madersbacher S, Klieber R, Mann K, et al.: Free α‐subunit, free β‐subunit of human chorionic gonadotropin (hCG), and intact hCG in sera of healthy individuals and testicular cancer patients. Clin Chem 38: 370–376, 1992. [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES